Telomere Therapeutics Establishes Scientific Advisory Board to Support the Advancement of its Gene Therapy Pipeline
January 2026 Telomere Therapeutics has established its Scientific Advisory Board (SAB), bringing together internationally recognized leaders in telomere biology, gene therapy, pulmonary medicine, translational research, and drug development to support the advancement of the Company’s therapeutic pipeline. The Scientific Advisory Board will provide strategic scientific and clinical guidance as Telomere Therapeutics advances AAV-TERT-01, its lead investigational gene […]
Telomere Therapeutics Receives EMA Orphan Drug Designation for AAV-TERT-01
December 2025 Telomere Therapeutics has been granted Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for AAV-TERT-01, its investigational gene therapy for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The designation recognizes the potential of AAV-TERT-01 to address a rare disease with significant unmet medical need and provides regulatory incentives to support its continued development, including protocol assistance, fee […]
Telomere Therapeutics Receives Comunidad de Madrid Grant Supporting EIC Accelerator Seal of Excellence Projects
December 2025 Telomere Therapeutics has been awarded a €2.3 million grant by the Comunidad de Madrid, through the Dirección General de Investigación e Innovación Tecnológica, following the Company’s successful receipt of the European Innovation Council (EIC) Accelerator Seal of Excellence under the Horizon Europe programme. The funding will support the continued development of AAV-TERT-01, the Company’s investigational gene therapy for Idiopathic Pulmonary Fibrosis (IPF). […]